May 06, 2020 Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
Apr 21, 2020 Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
Mar 11, 2020 Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
Jan 13, 2020 Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Nov 08, 2019 Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 07, 2019 Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
Sep 30, 2019 Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019